v3.26.1
Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Total
Series B Non-Voting Convertible Preferred Stock
Series C Non-Voting Convertible Preferred Stock
Preferred Stock
Preferred Stock
Series B Non-Voting Convertible Preferred Stock
Preferred Stock
Series C Non-Voting Convertible Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2024       161            
Beginning balance (in shares) at Dec. 31, 2024             1,316,989      
Beginning balance at Dec. 31, 2024 $ 15,831     $ 1,360       $ 291,898 $ (277,524) $ 97
Stock-based compensation expense 179             179    
Issuance of common stock in connection with vesting of restricted stock units (in shares)             5,370      
Issuance of common stock in connection with vesting of restricted stock units 29             29    
Other comprehensive income (loss), net 203                 203
Net Income (Loss) (2,533) $ 0 $ 0           (2,533)  
Ending balance (in shares) at Mar. 31, 2025       161            
Ending balance (in shares) at Mar. 31, 2025             1,322,359      
Ending balance at Mar. 31, 2025 13,709     $ 1,360       292,106 (280,057) 300
Beginning balance $ 1,341                  
Beginning balance (in shares) at Dec. 31, 2025 159     159            
Beginning balance (in shares) at Dec. 31, 2025         16,366 43,882 1,597,321      
Beginning balance at Dec. 31, 2025 $ 240,380     $ 1,341 $ 117,621 $ 297,291   310,688 (487,363) 802
Stock-based compensation expense 3,134             3,134    
Conversion of Series C Preferred Stock issued in connection with the asset acquisition of Damora Therapeutics, Inc (in shares)           (2,364) 2,364,000      
Conversion of Series C Preferred Stock issued in connection with the asset acquisition of Damora Therapeutics, Inc           $ (16,990)   16,990    
Issuance of common stock in connection with offering, net of issuance costs of $20,753 (in shares)             16,644,737      
Issuance of common stock in connection with offering, net of issuance costs of $20,753 $ 295,497             295,497    
Stockholder approval of the issuance of common stock upon conversion of Series C non-voting convertible preferred stock (in shares)           (39,641) 39,641,000      
Stockholder approval of the issuance of common stock upon conversion of Series C non-voting convertible preferred stock           $ (266,811) $ 1 266,810    
Forfeiture of shares (in shares)             (9,638)      
Issuance of common stock in connection with vesting of restricted stock units (in shares)             5,292      
Exercise of stock options (in shares) 60,500           60,500      
Exercise of stock options $ 423             423    
Other comprehensive income (loss), net (48)                 (48)
Net Income (Loss) $ (27,783) $ (5,789) $ (664)           (27,783)  
Ending balance (in shares) at Mar. 31, 2026 159     159            
Ending balance at Mar. 31, 2026 $ 1,341                  
Ending balance (in shares) at Mar. 31, 2026         16,366 1,877 60,303,212      
Ending balance at Mar. 31, 2026 511,603     $ 1,341 $ 117,621 $ 13,490 $ 1 $ 893,542 $ (515,146) $ 754
Beginning balance $ 1,341